The software assists radiologists during reviews of CT colonography (CTC, a.k.a. virtual colonoscopy) images by automatically highlighting potential colorectal polyps, which are possible precursors to colorectal cancer.
Medicsight PLC and Ziosoft Inc., have announced the integration of Medicsight’s ColonCAD API software and Ziosoft’s Ziostation. Ziosoft, based in Redwood City, Calif., will distribute the technologies in the United States under the terms of the deal.
The FDA approved ColonCAD API for clinical use in May. The software assists radiologists during reviews of CT colonography (CTC, a.k.a. virtual colonoscopy) images by automatically highlighting potential colorectal polyps, which are possible precursors to colorectal cancer. The FDA’s green light came after a clinical trial involving 15 radiologist readers who each reviewed 112 patient CT colonography cases. When assisted by ColonCAD, radiologists’ accuracy for detecting polyps of all sizes was significantly improved compared with unassisted reading, Medicsight officials said.
“The partnership between Ziosoft and Medicsight should make a compelling match for CT colonography interpretation,” said Perry J. Pickhardt, professor of Radiology at the University of Wisconsin, one of the first U.S. sites slated to use the combined Medicsight and Ziosoft technologies. “CTC will definitely benefit from the pairing of these companies which are two recognized leaders in the advanced visualization field.”
Ziosoft holds numerous clearances for applications for its supercomputing visualization and functional analytics technology. Medicsight and Ziosoft have been partnering in Europe prior to the U.S. clearance of ColonCAD software.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.